Related Experiment Videos
Neoadjuvant chemotherapy for resectable non-small cell lung cancer
E J Finkelstein1, J D Urschel, H Takita
1School of Medicine, State University of New York at Buffalo, USA.
Journal of Experimental & Clinical Cancer Research : CR
|March 20, 1998
Summary
Neoadjuvant chemotherapy may be feasible for resectable non-small cell lung carcinoma (NSCLC). This approach showed benefits in three localized NSCLC patients, potentially improving surgical outcomes.
Area of Science:
- Oncology
- Thoracic Surgery
Background:
- Surgical resection is the primary curative treatment for localized non-small cell lung carcinoma (NSCLC).
- Neoadjuvant chemotherapy is established for Stage III NSCLC, prompting investigation into its use for earlier stages.
- Optimizing outcomes for resectable NSCLC (Stage I and II) remains an area of active research.
Observation:
- Three patients with localized NSCLC received neoadjuvant chemotherapy.
- The first patient with poor pulmonary function experienced tumor shrinkage, enabling a more conservative resection.
- The second patient, initially suspected of having metastatic disease, showed a significant response, confirmed as primary lung cancer.
- The third patient with resectable NSCLC demonstrated an excellent response to neoadjuvant chemotherapy.
Findings:
- Neoadjuvant chemotherapy demonstrated feasibility in resectable NSCLC.
- Tumor size reduction facilitated less invasive surgical procedures.
- Positive responses suggest potential for improved therapeutic outcomes in early-stage NSCLC.
Implications:
- Neoadjuvant chemotherapy could be a beneficial addition to the treatment of resectable NSCLC.
- This approach may enhance the suitability and extent of surgical resection.
- Further research is warranted to establish the role of neoadjuvant chemotherapy in early-stage NSCLC management.